Metronomics Global Health Initiative

Home page > Publications > MGHI papers > Metronomic Chemotherapy with the (...)

Metronomic Chemotherapy with the COMBAT Regimen in Advanced Pediatric Malignancies: A Multicenter Experience

The team of Pr J. Sterba from the department of Pediatric Oncology,School of Medicine, Brno, Czech Republic, has published the experience with the COMBAT metronomic regimen in 3 european institutions. The manuscript is accepted for publication in Oncology. The ful data will be presented during the 3rd Metronomic Meeting in Haifa. MGHI is associated with this publication.


Background: The outcome of children with refractory/re- lapsed malignancies remains poor and novel therapies are urgently required. One of the promising approaches is met- ronomic chemotherapy. We present the clinical results of 74 children with advanced solid tumors treated according to treatment recommendation with data registry in three European pediatric centers. Methods: COMBAT (Combined Oral Metronomic Biodifferentiating Antiangiogenic Treatment) included low-dose daily temozolomide, etoposide, celecox- ib, vitamin D, fenofibrate and retinoic acid. From 2004 to 2010, 74 children were enrolled. Results: The 2-year overall survival (OS) was 43.1% (median 15.4, range 1.3–69.9 months). Of the 74 patients, 50 patients (68%) died and 24 are alive: 6 (8%) with progressive disease, 7 (9%) with stable disease/ partial response and 11 (15%) in complete response. Median time to response was 6 months. Of 62 patients with initially measurable disease, 25 (40%) had radiological response or stable disease. Fourteen of 25 showing clinical benefit re- sponded within the first 6 months. The treatment was well tolerated on an outpatient basis. Regarding non-hemato- logical toxicity of grade 62, hepatotoxicity of grade 3 oc- curred in 8 children and grade 3 cheilitis in 16 children. Conclusion: COMBAT is a feasible and effective treatment option for patients with relapsing/refractory malignancies. The treatment is well tolerated with a low acute toxicity profile.